Investment Thesis
Bio-Rad demonstrates exceptional profitability with a 29.4% net margin and strong balance sheet fundamentals, but growth stagnation (0% revenue YoY) and critically weak operating margin of 1.8% raise concerns about operational efficiency and sustainability. The dramatic 141% net income spike appears driven by non-operating items rather than core business improvement, warranting caution despite solid liquidity and cash generation.
Strengths
- Exceptional net profit margin of 29.4% indicating strong bottom-line profitability despite operational challenges
- Fortress balance sheet with debt/equity of 0.16x, current ratio of 5.62x, and substantial free cash flow of $374.6M
- Strong free cash flow generation of $374.6M ($14.5% FCF margin) provides financial flexibility and reinvestment capacity
Risks
- Flat year-over-year revenue growth of 0% signals stalled top-line expansion and potential market maturity or competitive pressures
- Dangerously low operating margin of 1.8% despite 51.9% gross margin suggests severe operational inefficiencies or cost structure problems
- Interest coverage ratio of 1.0x indicates minimal debt service cushion; net income surge appears anomalous (141% YoY) and likely unsustainable, suggesting one-time gains masking underlying weakness
Key Metrics to Watch
- Revenue growth trajectory and segment performance to determine if 0% growth is temporary or structural
- Operating margin expansion and cost structure optimization to validate core business profitability
- Source of net income spike to assess sustainability and distinguish between operating improvements vs. one-time gains
Financial Metrics
Revenue
2.6B
Net Income
759.9M
EPS (Diluted)
$27.85
Free Cash Flow
374.6M
Total Assets
10.6B
Cash
529.8M
Profitability Ratios
Gross Margin
51.9%
Operating Margin
1.8%
Net Margin
29.4%
ROE
10.2%
ROA
7.2%
FCF Margin
14.5%
Balance Sheet & Liquidity
Current Ratio
5.62x
Quick Ratio
4.19x
Debt/Equity
0.16x
Debt/Assets
29.5%
Interest Coverage
0.96x
Long-term Debt
1.2B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-21T02:12:17.698945 |
Data as of: 2025-12-31 |
Powered by Claude AI